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INTRODUCTION
Drug hypersensitivity syndrome (DHS) refers to a severe,
potentially life-threatening, drug reaction. To better indi-
vidualize this drug reaction, the term ‘‘Drug Rash with
Eosinophilia and Systemic Symptoms (DRESS) syndrome’’
has recently been used. 
DRESS syndrome was first introduced in 1996 by Boc-
quet et al. (1). Fever, rash, lymphadenopathy, and internal
organ involvement with marked eosinophilia constitute the
main manifestations. The most frequently involved organ is
the liver, followed by the kidney and lungs. The most fre-
quently incriminated drugs are anticonvulsant, sulfonamides,
dapsone, allopurinol, minocycline, and gold salt. The patho-
physiology of DRESS syndrome remains unclear, but a defect
in detoxification of causative drug, immunological imbal-
ance, and infections such as human herpes virus type 6 (HHV
6) have been suggested (2). The overall mortality in DRESS
is about 10% and occurrs in patients with severe multi-organ
involvement (1). 
We report here a case of DRESS syndrome induced by
celecoxib and anti-tuberculosis (Tb) drugs including isoni-
azid, rifampicin, ethambutol, and pyrazinamide in a patient
presented first as knee joints pain. 
CASE REPORT 
A 29-yr-old woman with no prior known medical illness
presented on March 2004 with an oral ulcer and knee joint
pain. She had no specific past medical history before. Cele-
coxib was prescribed by a rheumatologist on 17 March
under the suspicion of arthritis.
During the course of routine clinical examination, one
pulmonary nodule was found in the left upper lung field on
chest radiography. High-resolution lung computed tomog-
raphy (CT) suggested active pulmonary tuberculosis. She
was treated with isoniazid, rifampicin, ethambutol, and
pyrazinamide from March 25th. On April 28th (34 and 42
days after the initiation of anti-Tb drugs and celecoxib, res-
pectively), she was hospitalized due to jaundice and hep-
atomegaly. 
On admission, her temperature was 38℃, blood pressure
was 90/60 mmHg, and heart rate was 90 beats per min. She
had an exanthematous rash on her trunk and limbs with some
pustules (Fig. 1), decreased bibasilar lung sound, icteric sclera,
hepatosplenomegaly, cervical lymphadenopathy, and posterior
pharyngeal wall injection. Blood cell counts showed hemoglobin
12.4 g/dL, leukocyte count 19,990/μ L (polymorphs 45.6%,
lymphocytes 28.4%, and eosinophils 12.4% [upper limit of
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Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) 
Syndrome Induced by Celecoxib and Anti-tuberculosis Drugs 
Drug Rash with Eosinophilia and Systemic Symptoms (DRESS) syndrome reflects
a serious hypersensitivity reaction to drugs, characterized by skin rash, fever, lymph
node enlargement, and internal organ involvement. So far, numerous drugs such
as sulfonamides, phenobarbital, sulfasalazine, carbamazepine, and phenytoin have
been reported to cause the DRESS syndrome. We report a case in a 29-yr-old female
patient who had been on celecoxib and anti-tuberculosis drugs for one month to
treat knee joint pain and pulmonary tuberculosis. Our patient’s clinical manifesta-
tions included fever, lymphadenopathy, rash, hypereosinophilia, and visceral involve-
ment (hepatitis and pneumonitis). During the corticosteroid administration for DRESS
syndrome, swallowing difficulty with profound muscle weakness had developed.
Our patient was diagnosed as DRESS syndrome with eosinophilic polymyositis by
a histopathologic study. After complete resolution of all symptoms, patch tests were
positive for both celecoxib and ethambutol. Although further investigations might be
needed to confirm the causality, celecoxib and ethambutol can be added to the list
of drugs as having the possibility of DRESS syndrome.
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normal (ULN) 6%]), and platelet count 261,000/μ L. On her
peripheral blood smear, neutrophilic leukocytosis with eosi-
nophilia was noted without atypical lymphocytosis. Labora-
tory data at the patient’s first admission are summarized in
Table 1. Serologic tests for viral infections including hepati-
tis A and B, Epstein-Barr virus, human immunodeficiency
virus, and cytomegalovirus were negative. Auto-antibody
screening revealed negative antinuclear antibody (ANA) and
anti-smooth-muscle antibody (SMA). A skin biopsy (Fig. 2)
showed intraepidermal eosinophil infiltration and spongio-
sis with pustule formation. Perivascular inflammatory cell
cuffing was also noted. The chest radiography showed right
pleural effusion with pneumonic consolidation. The previ-
ous nodule in the left upper lung showed no interval change.
DHS was suspected and all anti-Tb drugs and celecoxib were
stopped. Intravenous methylprednisolone (1,000 mg daily)
for DHS and antimicrobial therapy (intravenous ceftriaxone
2 g daily and amikacin 1 g daily) for pneumonia were admin-
istered for 5 days, followed by oral prednisone 75 mg daily
and ursodeoxycholic acid 200 mg three times daily. Fever
and rash gradually resolved and liver function started to
improve. She was discharged on day 19 (17 May). 
Seven days later (24 May), the patient was readmitted. She
took her medicine intermittently after discharge. She present-
ed with a rash on forearm, sore throat, myalgia, swallowing
difficulty, and dyspnea. Over the next 3 days, she was febrile
up to 38℃, and the rash extended to whole body with vesi-
cle and pustule formation. Laboratory findings at second
admission are also outlined in Table 1. The CT scan of ab-
domen showed hepatomegaly with perihepatic fluid collec-
tion. A bone marrow biopsy disclosed moderate hypercellu-
lar marrow with diffuse infiltration of eosinophils. 
The diagnosis of a recurrent DRESS syndrome was made,
and methylprednisolone 1,000 mg daily was infused intra-
venously for 3 days. On day 4 of readmission, myalgia and
swallowing difficulty became more profound and muscle
weakness developed. Right biceps muscle biopsy (Fig. 3)
showed diffuse endomysial and perimysial infiltration of
eosinophils with myonecrosis. Her serum creatine kinase
(CK) increased up to 18,943 IU/L (ULN 217 IU/L), and elec-
tromyography showed typical myopathic changes. Tests were
negative for SMA and anti Jo-1 antibodies. A diagnosis of
eosinophilic polymyositis was made. Intravenous cyclosporine
100 mg daily and oral methylprednisolone 60 mg daily were
Fig. 1. Diffuse erythema on the patient’s right arm (A) and both legs (B).
B A
Admission date 
(yr. month. day)
Before admission
2004. 3. 17
1st admission
2004. 4. 28
2nd admission
2004. 5. 24
3rd admission
2004. 9. 13
Outpatient ward
2005. 6. 30
Leukocyte (cell count/μ L) 11,670 19,990 20,350 17,020 5,680*
Eosinophil (cell count/μ L) 140 2,478 4,477 1,361 278*
ALT (IU/L) (ULN 40 IU/L) 13 327 211 166 10*
AST (IU/L) (ULN 40 IU/L) 20 621 383 196 28*
ALP (IU/L) (ULN 280 IU/L) 306 788 324 3,314 288*
TB (mg/dL) (ULN 1.3 mg/dL) 0.50 3.63 1.58 7.34 0.97*
CRP (mg/dL) (ULN 0.5 mg/dL) 5.81 8.64 3.41 4.20 0.33*
CK (IU/L) (ULN 217 IU/L) Not checked 70 18,943 18 Not checked
Table 1. Laboratory values at each admission time-point
*Laboratory values at the end of steroid tapering.
ULN, upper limit of normal; ALT, alanine transaminase; AST, aspartate transaminase; ALP, alkaline phosphatase; TB, total bilirubin; CRP, C-reactive
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initiated. However, respiratory muscle weakness exacerbat-
ed requiring mechanical ventilatory support with intravenous
immunoglobulin (IVIG) infusion (1 g/kg/day for 2 days) on
day 8 of readmission. After 2 weeks of mechanical ventila-
tion, her respiratory function improved and the ventilator
was weaned. At that time, a trans bronchial lung biopsy dis-
closed chronic granulomatous inflammation without signif-
icant eosinophilic infiltrate and a sputum AFB stain revealed
a positive finding. Anti-Tb treatment with second-line drugs
(cycloserine 500 mg daily, ofloxacin 400 mg daily, prothion-
amide 250 mg daily, and streptomycin 1 g five times week-
ly) was restarted on June 12th, and cyclosporine was discon-
tinued on June 27th. After two more cycles (each cycle includ-
ed 2 days of immunoglobulin infusion [1 g/kg/day]) of IVIG,
skin lesions and liver function improved. The prednisone
was gradually tapered to 40 mg daily, and the patient was
discharged on July 9th. 
Over the next two months, the prednisone dosage was
reduced to 20 mg daily and an azathioprine (AZT) 50 mg
daily was added on August 27th because her serum alanine
aminotransferase (ALT) level was fluctuating and we worried
about the side effect of long-term steroid therapy in the patient
with Tb. Two weeks after initiation of AZT, she had a return
of fever, up to 37.6℃, jaundice, and a tender liver. Labora-
tory findings at the third admission showed a cholestatic
pattern, which was common in AZT toxicity (Table 1). AZT
was stopped on September 12th, and only oral prednisone
was maintained at a dosage of 10 to 20 mg daily with one
more cycle of IVIG. Afterwards, the serum ALT level became
normalized and complete resolution of all symptoms was
achieved 14 months after discontinuation of the celecoxib
and first line anti-Tb drugs. Prednisone was completely taper-
ed in June 2005. 
Four weeks after discontinuation of the prednisone, patch-
testing was performed with the celecoxib and first-line anti-
Tb drugs to evaluate a causal relationship. Tablets were crush-
ed and incorporated at 10% and 50% in white petrolatum.
The results showed diffuse erythematous rash around the
celecoxib, rifampicin, and ethambutol at day 2. Then, the
rash was localized to the celecoxib and ethambutol at day 4,
and it was more prominent near the celecoxib (Fig. 4). Taken
together, her episode was more likely induced by the cele-
coxib which probably played a major contributory role, and
other first-line anti-Tb drugs played a minor contributory
role. Second-line anti-Tb drugs were administered until Octo-
ber 2005. Her liver function had been completely normal-
Fig. 4. Patch test results to celecoxib and anti-Tb drugs.
50% in 
petrolatum
Patch test on day 4
Celecoxib INH RFP EMB PZA
10% in 
petrolatum
Fig. 2. Histologic examination shows intraepidermal eosinophil
infiltration and spongiosis. Perivascular inflammatory cell cuffing
is also noted. Hematoxylin and eosin stain (H&E), ×400.
Fig. 3. On histologic examination, myofibers show atrophy and
degenerative changes. Interstitial eosinophilic and lymphocytic
infiltration is noted. H&E, ×400.524 J.H. Lee, H.-K. Park, J. Heo, et al.
ized without recurrence of symptoms, and follow-up lung
CT also showed complete resolution of pulmonary Tb.
DISCUSSION
Our patient was diagnosed as DRESS syndrome as defined
by Bocquet et al. (1). Clinical features were typical: fever,
lymphadenopathy with pharyngitis, rash followed by exfo-
liative dermatitis, hypereosinophilia >1,500/μ L, and visceral
involvement (hepatitis and pneumonitis). The symptoms
began 34 and 42 days after the introduction of anti-Tb drugs
and celecoxib, respectively, in our patient. 
The side effects reported with celecoxib have been gener-
ally benign exanthemas. Recently, two cases of severe drug
hypersensitivity syndrome due to celecoxib have been report-
ed (3). In both cases, the celecoxib patch tests were positive.
In the first 2 yr of marketing, the reporting rate for Stevens-
Johnson syndrome/toxic epidermal necrolysis with celecox-
ib was 6 cases per million person-years of use (4). The report-
ing rate was somewhat higher than the background rate of
1.9 cases per million population per year. In our patient,
celecoxib was not suspected at first as the causative drug,
but in the patch test it showed stronger reaction than other
anti-Tb drugs.
Celecoxib, a selective cyclo-oxygenase-2 inhibitor, is a
diaryl-substituted pyrazole derivative containing a sulfon-
amide substituent. Sulfonamide is one of the most frequent-
ly incriminated drugs in DRESS syndrome. The aromatic
amine portion of the sulfonamide is considered to be critical
in the development of hypersensitivity syndrome. Since cele-
coxib does not contain the aromatic amine, adverse reactions
such as hypersensitivity syndrome and toxic epidermal necrol-
ysis would not be expected to occur at the same frequency
as they do with sulfonamides. Reports showing lack of cross-
reactivity balance the few case reports suggesting cross-reac-
tivity (5). In the present case, we also considered the possi-
bility of transferring the aromatic amine portion from anti-
Tb drugs to celecoxib, but we did not verify such a reaction
in vitro.
Our patient’s patch tests were positive to both celecoxib
and ethambutol. In the test, rifampicin also showed positive
reaction on day 2 but disappeared on day 4, then interpret-
ed as an irritant reaction. However, the patch test result is
not a confirmative one, and the rifampicin allergy with a
negative patch test also has been reported previously (6). 
Ethambutol is a relatively safe drug. In a study by Pitt (7),
there were less than 2% of adverse reactions in the 2,000
patients who received 15 mg/kg ethambutol. Skin reactions
due to ethambutol included hair loss, urticaria, erythema
multiforme, angioedema, hyperhidrosis, skin striae, bullous
eruptions, and exfoliative dermatitis (8). But a severe cuta-
neous reaction of toxic epidermal necrolysis associated with
ethambutol has been reported (9). In a review of the litera-
ture, we could not find other case report of DRESS syndrome
attributable to ethambutol.
Clinical and pathologic findings of our patient were con-
sistent with eosinophilic polymyositis (EM). Eosinophilic
myositis is a clinically and pathologically diverse group of
inflammatory muscle diseases associated with blood and/or
tissue eosinophilia (10). Clinical presentation of EM is dis-
tinct from other eosinophilic myositis. Tender muscle swelling
associated with proximal weakness accompanies a systemic
illness. The etiologies of eosinophilic myopathy include par-
asitic infection, vasculitis, malignancies, and idiopathic hyper-
eosinophilic syndrome. The pathogenesis remains unclear.
An increase in eosinophil production and activation mediat-
ed by cytokines like interleukin (IL)-5 are thought to play
an important role. Elevated muscle IL-5 induces local accu-
mulation of eosinophils and the subsequent release of eosi-
nophilic granular proteins. This eosinophilic degranulation
is blocked by cyclosporin A and prednisone (11). In the same
way, internal organ involvement by eosinophil infiltration
in DRESS syndrome is also thought to be induced by IL-5.
Systemic corticosteroids can inhibit the effect of IL-5 on eosi-
nophil accumulation and reduce the symptoms of DRESS
syndrome (12, 13).
In the present case, respiratory muscle weakness progressed
resulting in the respiratory failure despite the cyclosporine
infusion. Such a fulminant EM following DRESS syndrome
is a rare association. IVIG with prednisone was administer-
ed after the onset of myositis, and the respiratory function
resumed with the resolution of DRESS syndrome and poly-
myositis. In the previous reports on recurrent DRESS syn-
drome, IVIG administration showed improvement (14). 
After complete resolution of our patient’s symptoms, lab-
oratory tests for anti-HHV 6 IgG antibody showed positive
reaction but the polymerase chain reaction for HHV6 DNA
was negative. So the confirmation of exact association with
HHV6 was not made. If HHV6 reactivation was a possibil-
ity, our patient’s recovery after IVIG therapy could be exp-
lained. Although the mechanism of IVIG treatment in DRESS
remains unknown, the therapeutic effects might be depen-
dent on functional capabilities of anti-virus IgG contained
in IVIG. So far, the only undisputed way to treat severe DHS
is prompt withdrawal of the offending drug. Systemic cor-
ticosteroid administration is classically reported in the case
of organ- or life-threatening disease (15).
In a severe DHS as in present case, provocation test is not
ethically recommended. Also, in such a case which involves
multiple complexed drugs, patch test may be a useful method
for detecting the culprit drugs (16). This approach has been
advocated in previous reports on DRESS syndrome (17, 18).
In conclusion, we report here a case of DRESS accompa-
nying EM, the cause of which might be associated with both
celecoxib and ethambutol according to the patch test. Cele-
coxib and ethambutol can be added to the list of drugs caus-
ing DRESS syndrome, but further investigations includingDRESS Syndrome Following Celecoxib and Anti-tuberculosis Drugs 525
lymphocyte toxicity assay might be needed to confirm the
causality.
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